Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

why do some patients benefit from immunotherapy while others do not? The current treatment for relapsed AML, donor lymphocyte infusion (DLI) -- a therapy involving donor immune cells -- has a 5 ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique T cells pivotal in treating relapsed acute myeloid leukemia. Their DIISCO ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

In this regard, natural killer (NK) cell-based immunotherapy has attracted clinical interest due to its critical role in immunosurveillance and their capabilities to target AML blasts. NK cells ...